Lynch Jc..Prevention of type 2 diabetes.Journ Pharm Pract. :
2.
Fertig Bj,Simmons Da,Martin DbDiabetes in America. 2Bethesda: National Institutes of Health; 1995:519-539.
3.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38).BMJ. 1998;317:703-713
4.
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39).BMJ. 1998;317:713-720
5.
Intensive blood-glucose control with sulphonylureas or insulin compared with traditional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).Lancet. 1998;352:837-853
6.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).Lancet. 1998;352:854-865
7.
Testa Ma,Simonson Dc..Health economic benefits and quality of like during improved glycemic control in patients with type 2 diabetes mellitus.JAMA. 1998;280:1490-1496
8.
Pyorala M,Miettinen H,Laakso M,Pyorala K..Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study.Circulation. 1998;98:398-404
9.
Hsueh Wa,Law Re..Cardiovascular risk continuum: implications of insulin resistance and diabetes.Am J Med. 1998;105:4S-14S
10.
A study of the effects of hypoglycemic agents on vascular complications in patients with adultonset diabetes: Mortality results.Diabetes. 1970;19:785-830
11.
Goldberg Rb,Einhorn D,Lucas Cp.A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.Diabetes Care. 1998;21:1897-1903
12.
Feinglos Mn,Bethel Ma..Treatment of Type 2 Diabetes Mellitus.Medical Clinics of North America. 1998;82:757-790
13.
Garber Aj..Metformin for type II diabetes mellitus.P&T. 1995;:568-583
14.
Hermann Ls,Schersten B,Bitzen Po.Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study.Diabetes Care. 1994;17:1100-1109
15.
Bush Wh,Bettman Ma..Metformin therapy and the risk of lactic acidosis.The American College of Radiology Bulletin. 1997;53:18-19
16.
Rasuli P,French G,Hammond I..New contraindication to intravascular contrast material (letter).Radiology. 1996;201:289
17.
Baily Cj..Biguanides and NIDDM.Diabetes Care. 1992;15:755-772
18.
18.Bayer Corp. Product Information for Precose.1995.
Saltiel Ar,Olefsky Jm..Thiazoledinediones in the treatment of insulin resistance and type II diabetes.Diabetes. 1996;45:1661-1669
21.
Nolan Jj,Ludvick B,Beerdsen P.Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglita-zone.N Engl J Med. 1994;331:1188-1193
22.
22.Parke-Davis. Data on file; 1998.
23.
Hayward Ra,Manning Wg,Kaplan Sh,Wagner Eh,Greenfield S..Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization.JAMA. 1997;278:1663-1669
24.
Lenhard Mj..Insulin treatment for type 2 diabetes (letter).JAMA. 1998;279:1523-1524
25.
Edelman Sv,Henry Rr..Insulin therapy for normalizing glycated hemoglobin in type II diabetes: Application, benefits, and risks.Diabetes Rev. 1995;3:308-334
26.
Feinglos Mn,Thacker Ch,English J.Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.Diabetes Care. 1997;20:1539-1542
27.
Fertig Bj,Simmons Da,Martin Db.Diabetes in America. 2Bethesda: National Institutes of Health; 1995:519-539.
28.
Riddle MC.Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine.Horm Metab Res. 1996;28:430-433
29.
Yki-Jarvin .N Eng J Med. 1992;327:1426-1433
30.
Reaven Gm,Johnston P,Hollenbeck Cb.Combined metformin-sulfonylurea treatment of patients with non-insulin dependent diabetes in fair to poor glycemic control.Journ Clin Endocrin Metab. 1992;74:1020-1026
31.
Jeppeson J,Chen Iy,Zhou My,Reaven Gm..Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.Diabetes Care. 1994;17:1093-1099
32.
UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes.Diabetes Care. 1998;21:87-92
33.
Chaisson Jl,Josse Rg,Hunt Ja.The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus.Ann Int Med. 1994;121:928-935
Thompson Rg,Gottlieb A,Organ K.Pramlintide: a human amylin analogue reduced postprandial glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.Diabet Med. 1997;14:547-555
36.
Thompson Rg,Pearson L,Schoenfeld Sl,Kolterman Og..Pramlintide, a synthetic analog of human amylin, improves metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group.Diabetes Care. 1998;21:987-993
37.
Laube Bl,Georgopoulos A,Adams Gk..Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients.JAMA. 1993;269:2106-2109
38.
Laube Bl,Benedict Gw,Dobs As..The lung as an alternative route of delivery for insulin in controlling postprandial glucose levels in patients with diabetes.Chest. 1998;114:1734-1739
